Grace Escamilla, MD
Internal Medicine · Cincinnati, OHNPI 1235525023
Payments from drug & device makers
Across 79 payments — averaging $16.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$222
- Novo Nordisk$197
- Welch Allyn$192
- Pfizer$112
- Johnson & Johnson$84
- Lilly USA, LLC$63
- plus $427 from 16 others
What the payments were for
- Food & beverage$1,10585%
- Other$19215%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 19 | $222 |
| Novo Nordisk | 17 | $197 |
| Welch Allyn | 1 | $192 |
| Pfizer | 7 | $112 |
| Johnson & Johnson | 5 | $84 |
| Lilly USA, LLC | 4 | $63 |
| Novartis | 4 | $62 |
| GSK | 3 | $61 |
| Astellas Pharma US Inc | 2 | $44 |
| AstraZeneca | 3 | $41 |
| Amarin Pharma, Inc. | 2 | $30 |
| Dynavax Technologies Corporation | 2 | $29 |
| Clarus Therapeutics Inc. | 1 | $20 |
| Nevro Corp. | 1 | $19 |
| Eisai Inc. | 1 | $18 |
| Boehringer Ingelheim | 1 | $17 |
| Shire North American Group Inc | 1 | $17 |
| Pacira Therapeutics, Inc. | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Insmed, Inc. | 1 | $14 |
| Insulet Corporation | 1 | $14 |
| Amgen | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NONE$192
How this compares
$1,297 in reported general payments places this provider in the 75th percentile of 4,428 internal medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 47 | $77,744 |
| TrulicityDulaglutide | 50 | $68,094 |
| JardianceEmpagliflozin | 44 | $57,866 |
| MounjaroTirzepatide | 39 | $53,730 |
| EliquisApixaban | 34 | $51,737 |
| MyrbetriqMirabegron | 49 | $32,879 |
| JanuviaSitagliptin Phosphate | 19 | $30,414 |
| XareltoRivaroxaban | 24 | $22,678 |
| FarxigaDapagliflozin Propanediol | 18 | $20,811 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $15,466 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 79 | $13,900 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $11,848 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $9,822 |
| Atorvastatin Calcium | 496 | $8,573 |
| SynthroidLevothyroxine Sodium | 62 | $5,525 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $63 | $121,82489 claims |
| Novo NordiskOzempic | $197 | $77,74447 claims |
| Boehringer IngelheimJardiance | $17 | $57,86644 claims |
| PfizerEliquis | $112 | $51,73734 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $61 | $37,13651 claims |
| Astellas Pharma US IncMyrbetriq | $44 | $32,87949 claims |
| MerckJanuvia | $222 | $30,41419 claims |
| AstraZenecaFarxiga, Symbicort | $41 | $25,20235 claims |
| Johnson & JohnsonXarelto | $84 | $22,67824 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,428 internal medicine providers in Ohio.
Other internal medicine in Cincinnati
- Antoinette PragalosCincinnati$27.8M
- Charles EgerCincinnati$8.7M
- Douglas LoganCincinnati$4.7M
- Leela VrishabhendraCincinnati$3.4M
- Traci TurnerCincinnati$645K
- Vincent MartinCincinnati$398K
- Lisa LarkinCincinnati$276K
- Mark EckmanCincinnati$255K
- Kay JohnsonCincinnati$184K
- Steven FolkerthBeavercreek$9.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.